INDIAN MARKET ENDS WEEK ON A HIGH NOTE DAILY MARKET WRAP UP nd

2 SEP 2016 S&P BSE 30

VALUE 28532.11

CHANGE 0.38%

NIFTY

8809.65

0.40%

JK TYRE

145.45

8.83%

RS/$

66.8300

0.04%

HCC

35.55

8.55%

43.75

1.39%

PVR

1282.80

8.42%

BSE MIDCAP BSE SMALL CAP NIFTY BANK

13230.94 12644.06 19883.20

0.49% 0.36% 0.48%

CHOLAFIN EIDPARRY

NIFTY AUTO

10052.95

1.14%

ADANIPORTS

268.80

3.90%

NIFTY FMCG

22789.30

0.32%

BANKBARODA

166.40

3.19%

NIFTY IT

10528.35

0.05%

TATAMTRDVR

351.95

2.22%

NIFTY PHARMA

11555.15

0.08%

BHARTIARTL

317.25

2.06%

NIFTY REALTY NIFTY MIDCAP 50 NIFTY NEXT 50

202.80 3913.95 23031.05

0.77% 1.24% 0.31%

COALINDIA RELIANCE ACC

332.05 1013.00 1667.00

1.76% 1.57% 1.22%

CRUDE OIL

GAINERS / LOOSERS

VALUE S&P BSE (In Rs)

1097.85 236.00 NIFTY 50 (In Rs)

CHANGE

6.04% 4.76%

MARKET COMMENTARY Indian stock markets said good morning with a strong positive opening. S&P BSE Sensex was up 89 points and Nifty 20 points from the very start. Buoyant august auto numbers, favorable government stance on infrastructure, construction and banking sector has made these sectors leaders for almost the whole week. Post lunch the market was up 148 points and scaled new one year high of 28571, Nifty on the other hand crossed 8800 and jumped 0.5% at 8817.20. With the markets performing well, a number of stocks have made fresh 52 week highs. For the day, Heromotocorp, Tata Motors, Dr Lal Pathlabs, to name a few to scaled new 52 week highs. Telecom sector was less volatile today as Bharti Airtel and Idea both moved up. Bharti Airtel was the biggest beneficiary as the stock closed 2.06% up and Idea 0.42% up. Reliance Industries on the other hand saw downtrend again today as the stock closed 1.57% down on the last trading day of the week. By the end of the day Sensex and Nifty gained 108 & 35 points respectively. Nifty closing at 8809 is the highest since April 2015. On the whole both Sensex and Nifty gained 2.7% this week.

JUNE QUARTERLY RESULTS MANGALORE CHEMICALS AND FERTILIZERS LTD

The Company posted a net loss of Rs. 83.61 million for the quarter ended June 30, 2016. Income from operations also declined 27% and stood at Rs. 5290.69 mn for the quarter ended 30th June 2016. The stock was up by 5.67% and closed at Rs. 47.85 by the end of the day. ALSTOM INDIA LTD

Alstom India reported weak quarterly numbers with net loss of Rs. 630 mn compared to profit of Rs. 124 mn in the same period previous year. Income from operations for the June quarter stood at Rs. 3854 mn compared to Rs. 4214 mn in June quarter previous year. The stock ended 0.29% up and closed at Rs. 599 by the end of the day.

COMPANY SPECIFIC NEWS WANDA EYES PVR STAKE

PVR stock was up as market rumors suggested Chinese giant Wanda Cinemas eyeing controlling stake in the company. PVR is one of the biggest multiplex chains in the country having 553 screens across 131 properties in 48 cities across India. PATEL ENGINEERING LTD

The stock was 20% up intraday as the company informed BSE that the recent decision of the government to pay 75% of the arbitration awards will enable it to retire 55-60% of the its debt. The total standalone debt of the company as on 31st March 2016 was Rs. 4535 crores. NATCO PHARMA

NATCO Pharma Limited has announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of its marketing partner, Mylan, in its inter partes review (IPR) proceeding and found all claims of U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd., unpatentable. This is the third patent related to Copaxone® 40 mg/mL to be found unpatentable in the last week. NATCO’s marketing partner Mylan believes it is one of the first companies to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/mL, and expects to be eligible for

180 days of marketing exclusivity in the U.S. upon final FDA approval. Copaxone® 40 mg/mL had U.S. sales of approximately $3.3 billion for the 12 months ending June 30, 2016. CADILA HEALTHCARE

Cadila Healthcare Ltd has informed BSE that the Company's Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. LARSEN & TOUBRO TECHNOLOGY SERVICES

Larsen and Toubro has announced that the price band of the Initial Public Offering of Equity Shares of the Company's Subsidiary, Larsen and Toubro Technology Services (LTTS) has been fixed between Rs. 850 to Rs. 860 per equity share. AUTO SALES FOR AUGUST 2016 COMPANY TVS MOTORS HEROMOTOCORP TATA MOTORS BAJA AUTO

GROWTH RATE % 24% 28% 6% 25%

CURRENT STOCK PRICE

CHANGE %

Rs. 331.85 Rs. 3578.55 Rs. 549.80 Rs. 2999.85

1.33% 0.89% 1.13% 0.11%

SUHANI ADILABADKAR [email protected] 9701063320

Disclaimer The information and opinions contained in the research reports have been compiled or arrived at from sources believed reliable but no representation or warranty, express or implied, is made as to their accuracy or completeness. The research report does not constitute a personal recommendation or take into

account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including but not limited to tax advice. The reports do not take into account the particular investment objectives, financial situations, risk profile or needs of individual clients. The user assumes the entire risk of any use made of this information. This report is not to be relied upon in substitution for the exercise of independent judgment. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Research data and reports published/ emailed/ text messaged via Short Messaging Services, Online Messengers, WhatsApp etc/transmitted through mobile application/s, including but not limited to FLIP™, Video Widget, telephony networks, print or electronic media and or those made available/uploaded on social networking sites (e.g. Facebook, Twitter, LinkedIn etc) is for informational purposes only. The reports are provided for assistance and are not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Though disseminated to clients simultaneously, not all clients may receive the reports at the same time. We will not treat recipients as clients by virtue of their receiving this report. The reports include projections, forecasts and other predictive statements which represent our assumptions and expectations in the light of currently available information. These projections and forecasts are based on industry trends, circumstances and factors which involve risks, variables and uncertainties. The actual performance of the companies represented in the report may vary from those projected. The opinions expressed in the reports are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. The reports are non-inclusive and do not consider all the information that the recipients may consider material to investments.

We shall not be in any way responsible for any indirect, special or consequential damages that may arise to any person from any inadvertent error in the information contained in the reports nor do they take guarantee or assume liability for any omissions of the information contained therein. Information contained therein cannot be the basis for any claim, demand or cause of action. These data, reports and information do not constitute scientific publication and do not carry any evidentiary value whatsoever. The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis. Prospective investors and others are cautioned that any forward-looking statements, if any, are not predictions and may be subject to change without notice. This report may provide the addresses of, or contain hyperlinks to websites. Except to the extent to which the report refers to material we take no responsibility whatsoever for the contents therein. Such addresses or hyperlinks are provided solely for your convenience and information and the content of the linked site does not in any way form part of this report. Accessing such website or following such link through this report shall be at your own risk. The author of this Research Report accepts no liability and will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report. This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.